



# Index

<b>Notes</b> Abbreviations used in index entries: ACE = angiotensin-converting enzyme ARB = angiotensin II receptor blocker CKD = chronic kidney disease ESRD = end-stage renal disease HUS/TTP = haemolytic uraemic syndrome/thrombotic thrombocytopenic purpura MCUG = micturating cystourethrogram NO = nitric oxide All index entries relate to renal disease and pregnancy unless otherwise indicated. <i>vs</i> denotes differential diagnosis.	ADAMTS <sub>13</sub> 180 adrenal suppression, fetal 134 adult polycystic kidney disease (APKD) 56 age, maternal, chronic hypertension in CKD and 154 albumin excretion diabetic nephropathy 111, 112, 119 normal pregnancy 33 serum levels 35, 38 tubular catabolism 37 aldosterone antagonists 144 alendronate, renal transplant recipients 240 alfacalcidol 239 ‘all or nothing’ effect, drug use, pre- embryonic stage 130 alpha-fetoprotein 40 Alport syndrome 56 American College of Rheumatology (ACR), lupus definition 96–7 American Society of Transplantation (AST) 76 aminoglycosides 39, 182 amlodipine 160 amniotic fluid volume 63, 65 amoxicillin 39 amyloidosis, renal 202 anaemia CKD 26, 141, 143, 238 fetal 139 management in dialysis patients 66 microangiopathic haemolytic 180 in renal transplant recipients 143, 231, 237–8 ANCA cytoplasmic-staining (c-ANCA) 97 perinuclear/nuclear-staining (p- ANCA) 97 ANCA-negative vasculitis 95 ANCA-positive vasculitis 95 case study, midwifery role 50 epidemiology 95 pregnancy outcome 103
--	--

Cambridge University Press

978-1-904-75259-2 - Renal Disease in Pregnancy

Edited by John M Davison, Catherine Nelson-Piercy, Sean Kehoe and Philip Baker

Index

[More information](#)

## 254 | INDEX

- angiogenesis, eNOS system role 13
- angiomylipoma (AML) 212, 217
  - ruptured 217
- angiotensin-converting enzyme (ACE)
  - inhibitors *see* ACE inhibitors
- angiotensin II 9
- angiotensin II receptor blockers (ARBs)
  - in CKD (nonpregnant women) 152
  - discontinuation in pregnancy 22–3, 24, 32, 34, 158, 194
  - renal transplant recipients 232
  - postpartum initiation 55
  - teratogenicity 24
- animal studies
  - NO-dependent renal vasodilation 8
  - renal haemodynamic changes 5
  - renal sodium excretion control 9–10
  - teratogenicity of drugs 130
  - VEGF deficiency in pre-eclampsia
    - model 13
- anion gap 36
- antenatal care
  - in CKD 31–41
    - case study 50
    - fetal wellbeing assessment 40–1
    - glomerular filtration rate 33
    - guidelines 41
    - hypertension 32–3
    - key principles 31–2
    - medication use 39
    - models 41
    - nephrotic syndrome 33–6
    - by obstetrician and renal physician 41
    - proteinuria 33–6
    - renal tubular function assessment 36–7
    - superimposed pre-eclampsia 39–40
    - underlying renal disease 36
    - urinary tract infections 37–8
    - visit schedule 41
    - volume homeostasis management 38
  - consensus views 250
  - in lupus nephritis 36, 107
  - in maternal hypertension 32–3, 154, 160
  - in renal transplant recipients 84
  - schedule, in CKD 41
  - in vasculitic nephritis 50, 107
- antenatal education, in renal disease 48
- antibiotic therapy
  - acute pyelonephritis 184–5, 211, 234
  - asymptomatic bacteriuria 211, 234
  - cystitis 211
  - urinary tract infections 38, 39, 90
- anti-C1q antibodies 97
- anticardiolipin antibodies 192, 241
- anti-CD20 antibodies (rituximab) 76, 106
- anticoagulation, in dialysis 66
- anti-dsDNA antibodies 97, 102
- antihypertensive therapy 32, 39, 158–60, 194
  - choice of drug 158–60, 194
  - in CKD in nonpregnant women 151–3
  - in CKD in pregnant women 156–60
  - discontinuation/tapering in pregnancy 76, 156, 157, 158
    - see also* ACE inhibitors
  - ‘double blockade’ (ACE inhibitors/ARBs), in nonpregnant women 153
  - drugs contraindicated in pregnancy 32, 34, 39, 159, 194, 232
    - see also* ACE inhibitors
  - fetal growth restriction association 161, 162
  - first-line agents 158, 159
  - indications 156, 157, 160, 194
  - mean arterial pressure fall induced by 161, 162
  - in mild essential hypertension 156–7, 160, 194
  - prepregnancy counselling review 24
  - rationale for use 157, 161
  - renal transplant recipients 232–3
  - in severe pre-eclampsia 195
  - transplacental transfer 158
    - see also* hypertension (maternal), management
- anti-La antibodies 241
- antineutrophil cytoplasmic antibody *see* ANCA
- ANCA
- antioxidants
  - renal transplant recipients 233
  - superimposed pre-eclampsia
    - prevention 156
- antiplatelet agents
  - HUS/TTP management 181
    - see also* aspirin, low-dose
- anti-Ro antibodies 241
- antithymocyte globulin (ATG) 76
- anti-TNF $\alpha$ , lupus nephritis 106
- anuria, acute renal cortical necrosis 181
- arachidonic acid, metabolism 156
- arginine vasopressin (AVP) osmoregulatory system 9
- arteriolar resistance 5
- aspirin, low-dose 39

Cambridge University Press

978-1-904-75259-2 - Renal Disease in Pregnancy

Edited by John M Davison, Catherine Nelson-Piercy, Sean Kehoe and Philip Baker

Index

[More information](#)

INDEX | 255

- in diabetic nephropathy 117
  - HUS/TTP management 181
  - pre-eclampsia prevention 25, 39, 117
  - renal transplant recipients 233
  - superimposed pre-eclampsia prevention 156
- assisted reproduction 167–76
  - in CKD 27, 174–5
  - complications 173
  - in vitro* fertilisation 83
  - pharmacology 172–3
  - in renal transplant recipients 82–3, 175
- asymptomatic bacteriuria (ASB) *see* bacteriuria, asymptomatic (ASB)
- atenolol 39, 159, 232
- atorvastatin 239
- atrial natriuretic peptide (ANP) 6, 9, 10
- atrial septal defect 234
- autoantibodies
  - in lupus nephritis 95, 97, 102
  - in renal transplant recipients 75
  - in SLE 75
- azathioprine 39, 135–6
  - breastfeeding and 136
  - in lupus nephritis 105–6
  - metabolism 131, 135
  - serum creatinine levels in pregnancy and 71, 74
  - teratogenicity 135
  - transplacental transfer 135
- bacteraemia 184
- bacteriuria, asymptomatic (ASB) 90, 183, 210–11
  - antibiotic treatment 210–11, 234
  - bowel segment incorporation into urinary tract 218
  - detection/confirmation 37, 211
  - incidence/prevalence 183, 210
  - renal transplant recipient 234
  - screening 90, 183, 211, 234
- barrier contraception, renal transplant recipients 82
- beta-adrenergic blockers 158–60, 194
  - renal transplant recipients 232
- beta-lactam antibiotics, in acute pyelonephritis 185
- betamethasone 134
- birth defects *see* congenital abnormalities
- bisphosphonates, renal transplant recipients 239–40
- bladder
  - cancer 217–18
  - carcinoma *in situ* 217
  - congenital abnormalities 182
  - physiological changes in pregnancy 209–10
  - in renal/pancreas transplantation 225
- bleeding, renal biopsy complication 201–2, 203
- blood pressure
  - antihypertensive drug indications 156, 157, 160, 194
  - automated recorders for 32
  - in diabetic nephropathy 117
  - hypertension definition 32
  - increase after delivery 33
  - increase in CKD 32
  - lability, after delivery 195, 197
  - lowering, adverse effect on fetal growth 229
  - measurement 32
  - mortality relationship, ESRD 152
  - normal changes in pregnancy 4, 5, 32, 150
  - prediction of worsening CKD 150
  - target
    - in CKD 32, 33, 151, 152
    - in diabetic nephropathy 117
    - in hypertension 156, 158, 160, 194, 195, 232
    - in severe pre-eclampsia 195
- see also* diastolic blood pressure; hypertension; systolic blood pressure
- blood volume
  - multiple pregnancies 173
  - ovarian hyperstimulation syndrome 174
  - total, in normal pregnancy 141, 142
- see also* plasma volume expansion
- B lymphocytes 80
- bone disease, in renal transplant recipients 239–40
  - management plan 230
- bone marrow suppression 135, 238
- bone mineral density, loss, glucocorticosteroid use 134
- breastfeeding
  - azathioprine use and 136
  - ciclosporin and tacrolimus use 139
  - corticosteroid use and 135
  - furosemide use and 144
  - guidelines on drug use whilst 133
  - mycophenolate mofetil use and 140
  - promotion and facilitation by
    - midwives 49
  - risks and benefits 49
  - sirolimus/everolimus use 141
- British National Formulary (BNF), drug use in pregnancy 132

Cambridge University Press

978-1-904-75259-2 - Renal Disease in Pregnancy

Edited by John M Davison, Catherine Nelson-Piercy, Sean Kehoe and Philip Baker

Index

[More information](#)

## 256 | INDEX

- bromocriptine 168
- buserelin 172
- C<sub>3</sub> and C<sub>4</sub> complement components, in
  - lupus nephritis 97, 102
- caesarean section
  - in chronic hypertension in CKD 153, 154
  - in diabetic nephropathy 115, 116, 117
  - renal transplant recipients 80, 224
  - after urinary tract reconstruction 218–19
- calcineurin inhibitors (CNIs) 75, 76, 80
- calcium
  - excretion 214
  - metabolism changes, dialysis associated 66
  - supplements 156, 233, 239
- calcium channel blockers 158, 160, 232
- calorie intake 66
- captopril, in diabetic nephropathy 113
- cardiovascular disease
  - CKD and 22, 149, 150
  - diabetic nephropathy with 113, 115, 120, 121
  - risk in renal transplant recipients 232
  - risk with renal abnormalities 55
- care, patterns *see* antenatal care;
  - pregnancy care
- caseload midwifery 46
- case study, ANCA-positive vasculitis,
  - midwifery care 50
- CD20, antibodies (rituximab) 76, 106
- cefalexin 38, 184, 234
- cefuroxime 184–5
- CellCept *see* mycophenolate mofetil
- CEMACH study 112, 119, 195
- central venous pressure monitoring 196
- cephalosporins 39
- cerebral palsy 122
- cervical neoplasia, post-renal transplant
  - 241–2
- childbirth, normal, definition 46
- children, of renal transplant recipients,
  - outcome 80, 81
- CHIP trial (blood pressure control in hypertension) 157, 161
- cholestasis, obstetric 138
- cholesterol, serum 35
- chronic kidney disease (CKD)
  - anaemia 26, 142, 143, 238
  - animal models, VEGF role 13
  - antenatal care *see* antenatal care
  - assisted reproduction 27, 174–5
  - cardiovascular disease risk 22
  - cardiovascular mortality 149, 150
  - definition 149
  - deterioration, blood pressure for
    - predicting 150
  - drug clearance 132–3
  - ethics of pregnancy 170–1
  - gestational GFR 4, 33, 40, 132–3, 149
  - haemoglobin decrease 142
  - hormonal disturbances 168
  - hypertension in 149–50
    - in nonpregnant women, treatment 151–3
    - in pregnancy *see under*
      - hypertension (maternal)
  - management in pregnancy 36
    - drugs 39, 129–47
    - general principles 31–44
  - MDRD equation (eGFR) 22
  - pregnancy renal function predictive
    - of outcome 3
  - prevalence 22, 149
  - progression risk, blood pressure and
    - protein excretion 152
  - progressive, ciclosporin *in utero*
    - association 138
  - proteinuria 133
  - risk quantification 25–7
  - severity, classification 133
  - sexual dysfunction *see* sexual
    - dysfunction, in CKD
  - stages, eGFR and 22
  - superimposed pre-eclampsia *see* pre-eclampsia
  - VEGF protective action 11
- Churg–Strauss syndrome 99, 104
- ciclosporin 39, 136–9
  - breastfeeding and 139
  - diabetes risk 241
  - in lupus nephritis 106
  - miscarriage association 136, 137
  - pharmacokinetics 138
  - pregnancy outcomes 136–9
  - renal transplant recipients 136–9
    - hypertension association 77, 138
    - levels in pregnancy, rejection 76
    - low birthweight and 79, 137, 139
    - perinatal mortality 78
    - serum creatinine levels and 71, 74
  - sirolimus use with 141
  - transplacental transfer 136
- CKD *see* chronic kidney disease (CKD)
- cleft palate, corticosteroids associated 134
- clomifene citrate 168, 172
- clonus 40
- Cochrane review, continuity of care 46

Cambridge University Press

978-1-904-75259-2 - Renal Disease in Pregnancy

Edited by John M Davison, Catherine Nelson-Piercy, Sean Kehoe and Philip Baker

Index

[More information](#)

- Cockcroft–Gault formula 33
- communication, facilitation, midwife's role 49
- computed tomography (CT), renal tract calculi 214
- Confidential Enquiry into Maternal and Child Health (CEMACH) 112, 119, 195
- congenital abnormalities
  - ACE inhibitors associated 24, 113, 158, 233
  - azathioprine association 135, 136
  - ciclosporin association 137
  - corticosteroids associated 134
  - drug use in first trimester 132
  - mycophenolate mofetil 139, 140
  - pregnancy in ESRD 170–1
  - see also* teratogenicity
- congenital abnormalities of kidney and urinary tract (CAKUT) 89–90
  - bladder/urethra 182
- congenital obstructive uropathy 182
- congenital toxoplasmosis 237
- connective tissue disease
  - postpartum follow-up 55–6
  - see also* systemic lupus erythematosus (SLE)
- consensus views 249–51
- continuity of care, midwifery 46–7
- contraception methods 24
  - renal transplant recipients 82
  - see also* intrauterine contraceptive device (IUCD)
- cordocentesis 119
- coronary artery disease, diabetic nephropathy with 113, 115, 120, 121
- corticosteroids 134–5
  - acute kidney rejection treatment 76
  - breastfeeding and 135
  - fetal risks 204–5
  - HUS/TTP management 181
  - maternal risks 134–5
  - preterm birth in diabetic nephropathy and 118
  - renal lupus flare control 105, 107
  - risks/benefits of use 134
  - transplacental passage 134
  - trial, in minimal change disease 204
- counselling
  - after pre-eclampsia 197
  - pregnancy outcome optimised in dialysis patients 64
  - prepregnancy *see* prepregnancy counselling
- COX-2 inhibitors 182
- creatinine, serum
  - abnormal level in pregnancy 33
  - in chronic hypertension in CKD 153, 154
  - in diabetic nephropathy 114
  - eGFR *vs*, CKD prevalence 22
  - elevated, in obstructed renal transplant 224
  - fall, in normal pregnancy 71
  - in lupus nephritis 96, 98, 102
  - postpartum, renal transplant recipients 74
  - postpartum follow-up and 53
  - in reflux nephropathy 91
  - in renal transplant recipients 71, 74, 224
  - risks associated with renal impairment levels 25
- creatinine clearance 33
  - in diabetic nephropathy 120, 121
  - measurement 33
  - normal changes in pregnancy 4, 33
  - renal impairment definition 96
- Crohn's disease 136
- crystalloid solutions, in severe pre-eclampsia 196
- cyclic guanosine monophosphate (cGMP)
  - increase in pregnancy 5–6
  - renal sodium retention and 9
  - renal tubular loss of responsiveness 9, 10
- cyclophosphamide 39
  - fetal abnormalities associated 106
  - in lupus nephritis 100, 106
- cystatin C 33
- cystitis 210
  - antibiotic treatment 211
  - haemorrhagic 210, 211
- cystoscopy 214
- cytomegalovirus (CMV) infection 235
- cytotoxic therapy, lupus nephritis 105–6
- decision making
  - advice against pregnancy and 27, 123
  - in high-risk pregnancy 27
  - loss of control in high-risk pregnancy 45
  - see also* informed decisions, by women
- delivery
  - indications in pre-eclampsia 40
  - see also* caesarean section; vaginal delivery
- depression 169
- dexamethasone 134
- Diabetes Control and Complications Trial (DCCT) 122

Cambridge University Press

978-1-904-75259-2 - Renal Disease in Pregnancy

Edited by John M Davison, Catherine Nelson-Piercy, Sean Kehoe and Philip Baker

Index

[More information](#)

## 258 | INDEX

- diabetes mellitus
  - effect on pregnancy 112
  - new-onset after transplant (NODAT) 240–1
  - in renal transplant recipients 231, 240–1
  - tacrolimus/ciclosporin-related risk 240–1
  - type 1 112, 113
    - postpartum follow-up 55
    - renal/pancreas transplantation 224–7
  - type 2 111
    - presentation in pregnancy 55
- diabetic nephropathy 111–25
  - ACE inhibitor use 112–13, 115
  - advice against pregnancy 123
  - blood pressure (target) 117
  - caesarean section 115, 116, 117
  - comorbidity 113–15, 120
    - cardiovascular disease 113, 115, 120, 121
    - screening for 115
  - creatinine levels 114
  - epidemiology 112–13
  - histology 111
  - long-term prognosis 119–22
    - maternal outcomes 119–22
    - neonatal/fetal outcomes 122
  - management 123, 151
  - microalbuminuria 111, 112
  - postpartum follow-up 55
  - pregnancy complications/outcome 111, 112, 115–19
    - factors affecting perinatal outcome 119
    - fetal growth restriction 116, 117
    - hypertension 112, 114, 117, 121
    - maternal death 120
    - perinatal death 111, 116, 117, 119
    - pre-eclampsia 117
    - preterm birth/delivery 116, 117, 118–19
    - proteinuria 114, 118, 121
    - thromboembolism 115, 117
  - pregnancy exacerbating 112, 119–22
  - pregnancy incidence in 112
  - progression risk, in pregnancy 119–20
  - renal transplant recipients 241
  - VEGF antagonism, protective action 13
- diabetic retinopathy 113, 122
- dialysis 61–8
  - assisted reproduction and 174–5
  - blood pressure target with 152
  - complications of pregnancy 63–4
  - early diagnosis of pregnancy 64
  - fetal/maternal monitoring 66–7
  - frequency/duration 63, 65
    - increased, problems associated 65–6
  - incidence of pregnancy 61–2
  - indications for, in pre-eclampsia 196–7
  - postmenopausal women, hormone levels 168
  - pregnancy outcomes 27, 61, 62–3, 170
    - fetal loss 27
    - strategies to optimise 64–7
  - pregnancy risks 23, 25, 27
  - prepregnancy counselling 23
  - protocol for pregnancy in 67
  - regimen changes to improve pregnancy outcome 65
    - see also* haemodialysis; peritoneal dialysis
- diastolic blood pressure
  - in chronic hypertension in CKD 153, 154
  - target, in hypertension 160, 194
- diet, after pancreas transplantation 225
- diltiazem 34, 160
- dipyridamole, HUS/TTP management 181
- disseminated intravascular coagulation (DIC)
  - in HUS/TTP 180
  - in lupus nephritis 101, 103
- diuretics 143–4
  - avoidance in pregnancy 39
  - renal transplant recipients 232
  - thiazide 159, 160
  - transplacental transfer 144
- dopamine-induced natriuresis 10
- double-J ureteric stent 214, 215
- drugs 129–47
  - to avoid in pregnancy 24, 32, 39, 236, 237
    - see also* antihypertensive therapy
  - clearance, in CKD 133
  - dose–response relationship 131
  - factors affecting exposure and impact 130–1
  - in first trimester 130, 132
  - metabolism 131
  - nephrotoxic, acute renal failure due to 182
  - prepregnancy counselling 22–3, 24–5, 129, 132
  - in second/third trimesters 132
  - teratogenicity *see* teratogenicity

Cambridge University Press

978-1-904-75259-2 - Renal Disease in Pregnancy

Edited by John M Davison, Catherine Nelson-Piercy, Sean Kehoe and Philip Baker

Index

[More information](#)

- timing of use, fetal development 130
  - use in pregnancy 129–47
    - guidelines 132–3
    - prescribing principles 132
  - see also individual drugs and drug groups*
- eclampsia, prevention 197
- ectopic pregnancy 173
- EDTA registry 74
- education
  - antenatal, in renal disease 48
  - consensus views 251
  - physicians, on risks of pregnancy 28
- embryotoxicity, sirolimus 141
- emotional needs of women, midwife's role
  - in recognising 49
- endoglin 13, 34
- endorphins, endogenous 168
- endothelial cells, VEGF role 11
- endothelin 8
  - type B (ET<sub>B</sub>) receptor 8
- end-stage renal disease (ESRD)
  - blood pressure, mortality relationship 152
  - carers, men as, and psychosocial issues 169
  - in diabetes mellitus 111, 112, 120, 122
  - dialysis for *see* dialysis
  - effect on pregnancy/fertility treatment 170
  - ethics of pregnancy 170–1
  - postpartum follow-up to avoid 54
  - pregnancy/fertility treatment effect on 170
    - issues affecting child after 170–1
  - reflux nephropathy causing 89, 91
  - sexual dysfunction *see* sexual dysfunction, in CKD
  - systolic hypertension 149
- epidural anaesthesia, in urolithiasis 215
- erythrocyte sedimentation rate (ESR),
  - vasculitic nephritis 103
- erythrocytosis, post-transplant 238–9
- erythropoietic-stimulating agents (ESA)
  - 141–3
    - adverse effects, and doses 143
- erythropoietin
  - increased plasma level 141–2
  - in normal pregnancy 237
  - requirement in dialysis 66
  - requirement in renal impairment 26
  - safety/efficacy in pregnancy 142–3, 238
- Escherichia coli*, urinary tract infection 38, 211, 234
- estimated glomerular filtration rate (eGFR) 22, 25, 149
- estrogens, renal vasodilation trigger 6
- ethics
  - of pregnancy in ESRD 170–1
  - of renal biopsy in pregnancy 203–4
- EURODIAB study 112, 122
- Euro-Lupus group 98, 99
- Euro-Lupus group definitions
  - non-renal flare 99
  - proteinuria 96
  - renal flare 98
- Euro-Lupus Nephritis trial 98
- European Best Practice Guidelines (EBPG), Expert Group on Renal Transplantation 76, 234
- everolimus 141
- fatty acid oxidation, mitochondrial, inborn error 182
- fatty liver of pregnancy *see* acute fatty liver of pregnancy (AFLP)
- fertility
  - impairment, prepregnancy counselling 24
  - after renal/pancreas transplantation 226–7
  - see also* infertility; subfertility
- fertility treatment 171
  - effect on renal disease 170
  - pharmacology 172–3
  - renal disease effect on 170
- fetal development, drug use timing 130
- fetal growth
  - adverse effect of blood pressure reduction 229
  - in renal transplant recipients 79
- fetal growth restriction 26
  - chronic hypertension in CKD 153, 161
  - diabetic nephropathy 116, 117
  - dialysis association 63
  - in renal impairment, risks 26
- fetal heart-rate monitoring, maternal dialysis and 67
- fetal loss
  - in diabetic nephropathy 111
  - dialysis and 27
  - in lupus nephritis (maternal) 101
  - in reflux nephropathy in pregnancy 91
  - see also* miscarriage; perinatal mortality
- fetal monitoring
  - hypertension in CKD 160–1
  - maternal dialysis and 66–7
- fetal outcome, lupus nephritis 100–2

Cambridge University Press

978-1-904-75259-2 - Renal Disease in Pregnancy

Edited by John M Davison, Catherine Nelson-Piercy, Sean Kehoe and Philip Baker

Index

[More information](#)

## 260 | INDEX

- fetal wellbeing, assessment 40
  - in CKD 40–1
  - in diabetic nephropathy 119
- fibroids 210
- fibromyalgia 98
- Flt<sub>1</sub> 11, 12
  - alternative splicing 13
  - soluble *see* sFlt<sub>1</sub>
- fluid balance
  - acute pyelonephritis management 184
  - pre-eclampsia-related renal impairment 195–7
- fluid loading, in pre-eclampsia 196
- fluid overload, prevention 195
- fluid restriction, post-delivery 196
- fluid volume status, maternal
  - acute shifts, preterm birth in dialysis and 64
  - management to improve pregnancy outcome 65
- follicle-stimulating hormone (FSH) 168, 172
- Food and Drug Administration (FDA) 132, 133, 135
- furosemide 144
- ganirelix 172
- general practitioners, postpartum follow-up 55
- gentamicin, intravenous 185
- gestational age, confirmation, in hypertension in CKD 160–1
- gestational diabetes, glucocorticosteroid use and 134
- glomerular capillaries
  - acute thrombosis 179
  - changes in pre-eclampsia 190, 191
- glomerular capillary pressure 5
  - increased 112
- glomerular disorders, renal tubular
  - function assessment 37
- glomerular endotheliosis 151, 190, 203
- glomerular fenestrae 11
- glomerular filtration rate (GFR)
  - antenatal care 33
  - cardiovascular risk and 150
  - in CKD 4, 33, 40, 132–3, 149
  - in diabetic nephropathy 112, 118
  - estimated (eGFR) 22, 25, 149
  - increase in normal pregnancy 4, 33, 71, 189, 209
  - reversal by nitric oxide synthase 6
  - increase mechanisms 3, 5–8
    - haemodynamics 5
    - vasoactive factors 5–6
  - measurement methods 33
  - in pre-eclampsia 189
  - renal impairment definition 96
  - in renal transplant recipients 71
  - superimposed pre-eclampsia in CKD 40
- glomerular hyperfiltration 112
- glomerulonephritis
  - crescentic, pauci-immune necrotising 96
  - diagnosis by renal biopsy 202, 203
  - primary 37
  - rapidly progressive 96, 97
- glomerulus
  - in pre-eclampsia 190, 191
  - VEGF actions 11
- glucocorticosteroids *see* corticosteroids
- glucose, decreased proximal tubular reabsorption 36
- glycaemic control 112, 113, 115, 122
- glycosuria 36, 210
- gonadotrophin-releasing hormone analogues 172
- gonadotrophins
  - adverse effects 172–3
  - for assisted conception 172
  - secretion 168
- goserelin 172
- granulomatous vasculitis 104
- guidelines
  - antenatal care in CKD 41
  - breastfeeding whilst on drug use 133
  - drug use in pregnancy 132–3
  - European Best Practice 76, 234
- haematocrit
  - erythropoietin indication 238
  - measurement 38
- haematuria 216–18
  - asymptomatic dipstick (ADH) 216–17
  - in lupus nephritis 97
  - macroscopic 217
    - in cystitis 210, 211
    - renal biopsy complication 202, 203
  - microscopic 23, 56, 216–17
  - renal trauma causing 217
  - in vasculitic nephritis 96, 97
- haemodiafiltration 64, 65
- haemodialysis
  - pregnancy outcome and 63, 170
  - regimen to improve pregnancy outcome 65
  - timing/duration 63, 65
  - see also* dialysis

- haemoglobin
  - decrease in CKD 142
  - glycosylated (HbA<sub>1c</sub>) 112, 122
  - in normal pregnancy 237
  - target levels 143
    - renal transplant recipients 238
- haemolytic anaemia
  - microangiopathic 180
  - see also* HELLP syndrome
- haemolytic uraemic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP) 179–81
  - clinical features 180, 193
  - differential diagnosis 193
  - management 180–1
  - pre-eclampsia *vs* 180, 193
- HbA<sub>1c</sub> 112, 122
- HELLP syndrome 13, 75, 193
  - differential diagnosis 193
  - recurrence 197
- Henoch–Schönlein purpura 99, 103, 104
- heparin
  - in nephrotic syndrome 35
  - see also* low-molecular-weight heparin
- hepatitis B 236–7
- hepatitis C 235–6
- herpes simplex infection 237
- human chorionic gonadotrophin (hCG)
  - assisted conception 172
  - fetal wellbeing assessment 40
- HUS/TTP *see* haemolytic uraemic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP)
- hydralazine 159, 194
  - in severe pre-eclampsia 195
- hydrochlorothiazide 144
- hydronephrosis 183, 211, 224
  - loin pain due to 212
  - management 215
  - ‘physiological’ 209, 212
  - pre-existing, before renal transplant 224
- hydrops fetalis 139, 144
- hydroxychloroquine 39
  - lupus nephritis 100, 102
- hypercalciuria 66, 214
- hyperemesis gravidarum 173
- hyperkalaemia, in acute renal cortical necrosis 181
- hyperlipidaemia, renal transplant recipients 239
- hypermagnesaemia, iatrogenic 66
- hyperparathyroidism 66
  - primary 239
  - secondary/tertiary 240
- hyper-reflexia 40
- hypertension
  - adult, after ciclosporin *in utero* association 138
  - childhood, in vesicoureteric reflux 89
  - risk after pre-eclampsia 197
  - risk quantification in CKD by 25
- hypertension (maternal)
  - antenatal care 32–3, 154, 160
  - blood pressure target 156, 158, 160, 194, 232
  - chronic 150, 153–4, 194
    - complications 153–4
    - pregnancy outcomes 153–4
    - severe 153
  - in CKD 149, 150
    - management *see below*
    - maternal evaluation 154
    - mechanisms 150, 156
    - superimposed pre-eclampsia 151, 153, 155–6
    - see also* pre-eclampsia
  - definition 32
  - in diabetic nephropathy 112, 114, 117, 121
  - drugs exacerbating
    - erythropoietic-stimulating agents 143
    - glucocorticosteroids 134
  - duration of pregnancy and 155
  - gestational 189
  - laboratory assessment 154
  - in lupus nephritis 101, 105, 107
  - management 32, 39, 149, 155–8
    - antenatal 193–4
    - antepartum assessment 160
    - antihypertensives *see* antihypertensive therapy
    - complicated hypertension 157–8
    - diuretic cautions 144, 160
    - fetal evaluation 160–1
    - initiation, blood pressure level 156, 157, 160, 232
    - mild essential hypertension 156–7, 160, 161
    - in pre-eclampsia-related renal impairment 193–5
    - rationale 195
    - in renal transplant recipients 229, 231, 232–3
    - secondary hypertension 157–8
    - severe hypertension 158
    - in severe pre-eclampsia 195
    - ‘tight’ *vs* ‘less tight’ (CHIP trial) 157, 161

Cambridge University Press

978-1-904-75259-2 - Renal Disease in Pregnancy

Edited by John M Davison, Catherine Nelson-Piercy, Sean Kehoe and Philip Baker

Index

[More information](#)

## 262 | INDEX

- postpartum 197
- postpartum follow-up 55
- pre-existing 150
- pregnancy outcome 31, 32, 90, 153–4
  - lupus/vasculitic nephritis 101, 105
- preterm birth associated with dialysis and 63
- prevalence 149
- prophylaxis 155–6
- renal biopsy 203
- in renal impairment, risks 26–7
- in renal transplant recipients 76–7, 229, 232–3
  - management plan 231, 232
- secondary 149, 150
  - management 157–8
- sequelae (long-term) 197
- systolic 149
- uncontrolled, pregnancy outcomes 27
- in vasculitic nephritis 105
- see also* pre-eclampsia
- hypertensive encephalopathy 158
- hyperventilation of pregnancy 66
- hypocalcaemia 239, 240
- hypocalciuria 156
- hypoglycaemia 182
- hypoglycaemic agents, oral 241
- hypogonadism 226
- hypophosphataemia, dialysis associated 66
- hypotension
  - in acute fatty liver of pregnancy 182
  - dialysis-induced 64
  - septic shock *vs* low intravascular volume 184
- ileal conduits 219
- immune system
  - effect of *in utero* exposure to immunosuppressants 80
  - neonatal abnormalities, renal transplant recipients and 138
- immunosuppressive drugs 39
  - breastfeeding risks with 49
  - in utero* exposure, effect on children after 80, 81, 171
  - in lupus nephritis 105–6, 200
  - minimisation in renal transplant recipient 234
  - prepregnancy counselling advice 24–5
  - renal transplant patient, anaemia 238
  - see also* corticosteroids; *individual drugs*
- infertility
  - rates in renal transplant recipients 82
  - treatment for 171
  - see also* fertility treatment; subfertility
- infliximab 106
- information sharing, pregnancy outcome in dialysis patients 64
- informed decisions, by women
  - midwife's role 48
  - pregnancy outcome optimised in dialysis 64
  - see also* decision making
- interferon, avoidance 236
- International Society for the Study of Hypertension in Pregnancy (ISSHP) 189
- interstitial nephritis 91
- intracytoplasmic sperm injection 83
- intrapartum care, by midwives 48
- intrauterine contraceptive device (IUCD)
  - azathioprine interference 136
  - renal transplant recipients 82
- intrauterine growth restriction (IUGR) *see* fetal growth restriction
- intravascular volume 38, 141
  - red blood cell volume/mass 141, 142, 237
  - reduced, in hypotension 184
  - see also* plasma volume expansion
- intravenous fluids 38
- intravenous immunoglobulin 76
  - in lupus nephritis 106
- intravenous urography (IVU) 213
- in vitro* fertilisation, renal transplant recipients 83
- iron
  - intravenous 143
  - loss, in haemodialysis 66
  - supplements, renal transplant recipients 238
- iron dextrose 238
- iron sucrose 238
- Joint National Committee in USA, 7th Report (JNC7) 151
- J stents
  - double-J ureteric stents 214, 215
  - ureteric obstruction 224
- KDR (VEGFR2) 11, 12
- kidney 217
  - injury *see* renal trauma
  - rupture 183
  - single 182
  - structural abnormalities, prepregnancy counselling 23
  - see also* entries beginning renal
- labetalol 158–60, 194
  - contraindication 195

- prepregnancy counselling advice 24
  - renal transplant recipients and 232
  - in severe pre-eclampsia 195
- lactate dehydrogenase (LDH) 75, 184
- lamivudine, avoidance 237
- lanthanum carbonate, avoidance 239
- leucopenia, azathioprine association 135
- liver transaminases, abnormal 40
- loin pain 211–14
  - acute renal obstruction 183, 224
  - causes 211–12
  - management 215
- low birthweight infants
  - azathioprine association 135
  - ciclosporin association 137
  - dialysis association 63, 67
  - renal transplant recipients 79
  - urinary tract infections associated 234
- lower urinary tract *see* urinary tract, lower
- low-molecular-weight heparin (LMWH) 35
  - in diabetic nephropathy 115
  - in dialysis patients 66
- lupus
  - cerebral 106
  - diagnosis 96–7
  - extrarenal disease 98–9
  - extrarenal flares 99, 101–2
  - renal disease *see* lupus nephritis
  - see also* systemic lupus erythematosus (SLE)
- Lupus Activity Criteria Count (LACC) 98
- lupus anticoagulant 192, 241
- lupus arthropathy 98
- lupus nephritis 95–109, 102
  - active, laboratory features 97, 102
  - antenatal care 36, 107
  - autoantibodies 97, 102
  - creatinine levels 96, 98, 102
  - diagnosis 97
  - disease activity 98
  - disseminated intravascular coagulation 101, 103
  - epidemiology 95–6
  - extrarenal flares 101–2
  - histological classification 97
    - maternal/fetal outcome 100
  - hypertension and 101, 105, 107
  - immunosuppression 105–6, 139
    - pregnancy outcome 100, 102
  - management 39, 104–7, 192
    - cytotoxic/immunosuppressive therapy 105–6, 139
    - plasma exchange 107
    - steroids 105
  - summary/key factors 107
  - new onset, in pregnancy 101
  - postpartum flares 102, 103
  - postpartum follow-up 54–5, 55–6
  - pre-eclampsia in 100, 103, 192
  - pre-eclampsia *vs* 97–8, 100
  - pregnancy and 99–103, 192
    - contraindication to 99
    - effect on renal outcomes in 102–3
    - management 99–100
    - risk of renal decline 103
    - therapeutic termination 106
  - pregnancy outcome 100–2
    - factors influencing 99, 100–2
  - fetal loss 100, 192
  - maternal death 102, 103, 105, 107
  - preterm birth 102, 241
  - pregnancy rates 96
  - prepregnancy counselling 23
  - proteinuria 96, 97
  - renal flares 97, 98, 101, 102, 192
    - control/management 105, 192
  - intrapartum 103
  - postpartum 102, 103
  - postpartum follow-up 55–6
  - prediction 102
  - renal transplant recipients 231, 241
  - renal tubular function assessment 37
- luteinizing hormone (LH) 168, 172
- macroalbuminuria, diabetic nephropathy 112
- magnesium, raised serum levels, dialysis and 66
- magnesium sulphate 197
- magnetic resonance urography (MRU), ureteric obstruction 185, 213
- marital problems 169
- maternal death
  - acute renal cortical necrosis 181
  - diabetic nephropathy 120
  - fluid management and 195
  - lupus nephritis 102, 103, 105, 107
  - vasculitic nephritis 104
- maternal survival, after renal transplant pregnancy 83
- Maternity Matters* 45, 48
- matrix metalloproteinase 2 (MMP2) 8
- mean arterial blood pressure (MAP), mortality relationship, ESRD 152
- men, psychosocial issues affecting carers 169
- menstruation
  - in CKD 168
  - irregular, after renal/pancreas transplantation 226

Cambridge University Press

978-1-904-75259-2 - Renal Disease in Pregnancy

Edited by John M Davison, Catherine Nelson-Piercy, Sean Kehoe and Philip Baker

Index

[More information](#)

## 264 | INDEX

- 6-mercaptopurine (6-MP) 131, 135
- mesentery, in urinary tract reconstruction 219
- metformin 241
- methyldopa
  - hypertension management 158, 159, 194
  - prepregnancy counselling advice 24
  - renal transplant recipients 232
- methylprednisolone 105, 134
- microalbuminuria, diabetic nephropathy 111, 112, 122
- micturating cystourethrography (MCUG) 56, 91
- midwife
  - as advocate or arbitrator 49
  - breastfeeding promotion and facilitation 49
  - communication in multidisciplinary team 49
  - experiences, of renal disease in pregnancy 47–8
  - interpretation of medical information 49
  - professional autonomy 47–8
  - role 45, 46, 48–9
    - case study 50
- midwifery 45–52
  - care, needs/expectations in high-risk women 47
  - caseload 46
  - challenges 46
  - continuity of care 46–7
  - medical model of care balance with 47
  - normal *vs* high-risk pregnancy 46
  - ‘risk’ label in renal disease 45–6
- minimal change disease, renal biopsy 204
- miscarriage
  - azathioprine association 135
  - ciclosporin association 136, 137
  - first-trimester
    - assisted reproduction complication 173
    - dialysis and 63
    - GFR increase absent 4
    - second-trimester, dialysis and 63
    - see also* fetal loss
- mitochondrial fatty acid oxidation, inborn error 182
- Modification of Diet in Renal Disease (MDRD) formula 22, 33
- mTOR (metabolic target of rapamycin) 141
- multidisciplinary team
  - communication facilitation, midwife’s role 49
  - consensus views 249
  - dialysis patients 64
  - lupus/vasculitic nephritis 104
- multiparity, renal transplant recipients 74–5
- multiple pregnancies
  - assisted reproduction complication 173
  - renal transplant recipients 74–5
  - risks associated 173
- Multiple Risk Factor Intervention Trial (MRFIT) 150
- mycophenolate mofetil (MMF) 39, 139–40
  - avoidance in pregnancy 24, 140
  - in breast milk 140
  - in lupus nephritis 106
  - management of use during pregnancy 140
- mycophenolic acid, enteric-coated (MPA) 139–40
- myelosuppression 135, 238
- National High Blood Pressure Education Program (NHBPEP) 194
- National Service Framework for Children, Young People and Maternity Services* 48
- National Transplantation Pregnancy Register (NTPR)
  - azathioprine use complications 135–6
  - ciclosporin use complications 137
  - mycophenolate mofetil use complications 140
  - renal/pancreas transplantation and pregnancy outcome 226
  - renal transplant and pregnancy/graft outcome 71, 72–3, 74, 79, 241
  - tacrolimus use complications 137
- natriuretic systems 8–9, 10
- neonatal death 26
  - in chronic hypertension in CKD 153, 154
- neonates
  - MCUG screening 56
  - outcome and impact of preterm birth 27
- nephirin 190
- nephritic flares 98
- nephritis
  - active, definition 97
  - lupus *see* lupus nephritis
  - new onset, in lupus 101
  - pre-eclampsia *vs* 97–8, 100
  - vasculitic *see* vasculitic nephritis

Cambridge University Press

978-1-904-75259-2 - Renal Disease in Pregnancy

Edited by John M Davison, Catherine Nelson-Piercy, Sean Kehoe and Philip Baker

Index

[More information](#)

INDEX | 265

- nephrolithotomy, percutaneous 215
- nephropathy
  - definition 112
  - diabetic *see* diabetic nephropathy
  - incipient, microalbuminuria 112
  - reflux *see* reflux nephropathy
  - risk and prevalence 112
- nephrostomy, percutaneous (PCN) 214, 215, 216
- nephrotic syndrome
  - antenatal care 33–6
  - complications/sequelae 35
  - pre-eclampsia causing 35, 190
  - protein/creatinine ratio (PCR) 35
  - renal biopsy 204
  - treatment 35
- neurodevelopment
  - children of diabetic nephropathy patients 122
  - children of renal transplant recipients 80, 81
- nifedipine 159, 160, 194
  - prepregnancy counselling advice 24
  - renal transplant recipients 232
- nitric oxide (NO)
  - increase in pregnancy 5–6
  - release triggered by Flt<sub>1</sub> 11
- nitric oxide synthase (NOS) 6
  - antibodies 6
  - endothelial (eNOS) 6, 13
  - inducible (iNOS) 6
  - neuronal (nNOS) 6
  - nNOS- $\alpha$  protein 6
  - nNOS- $\beta$  protein 6, 8
- nitrite/nitrate, inorganic (NO<sub>x</sub>) 5–6
- nitrofurantoin 39, 185
- nocturia 210
- nonsteroidal anti-inflammatory drugs (NSAIDs) 182, 215
- Nursing and Midwifery Council, Code of Professional Conduct 47
- ‘nutcracker syndrome’ 217
- nutrition, pregnancy outcome in dialysis patients 66
- obstetric complications
  - multiple pregnancies 173
  - previous pregnancies 28
- obstructive uropathy
  - congenital 182
  - see also* ureteric obstruction; urinary tract, obstruction
- oedema 35
  - pre-eclampsia 143
- oligohydramnios 64, 65
- oliguria 193
- oncotic pressure, in diabetic nephropathy 118
- oral contraception, renal transplant recipients 82
- organogenesis 130
- osmolality (plasma/serum) 37
  - fall in normal pregnancy 8
  - ovarian hyperstimulation syndrome 174
- osteopenia, renal transplant recipients 239, 240
- osteoporosis, renal transplant recipients 239
- ototoxicity, furosemide 144
- ovarian hyperstimulation syndrome (OHSS) 174, 210
  - clomifene citrate associated 172
- over-distension syndrome 183
- ovum donation 7
- pain
  - loin *see* loin pain
  - renal biopsy complication 201
- pancreas after kidney transplantation 225
- pancreas/kidney transplantation *see* renal/pancreas transplantation
- pancreas transplantation 224, 225
  - principles 225
- parathyroidectomy 239, 240
- parathyroid hormone (PTH), abnormal levels 239
- parathyroid hormone-related protein (PTH-rP) 66
- parity, diabetic nephropathy risk 122
- patent ductus arteriosus 144
- patterns of antenatal care *see* antenatal care
- PCR *see* protein/creatinine ratio (PCR)
- pelviureteric junction obstruction (PUJO) 212
- perception of risks in pregnancy 45
- percutaneous nephrolithotomy (PCNL) 215
- percutaneous nephrostomy (PCN) 214, 215, 216
- percutaneous renal biopsy *see* renal biopsy
- perinatal mortality
  - diabetic nephropathy 116, 117, 119
  - renal transplant recipients 78
  - see also* fetal loss; neonatal death
- peritoneal dialysis
  - pregnancy outcome and 63, 170
  - regimen to improve pregnancy outcome 65
  - see also* dialysis
- pharmacokinetics
  - in CKD 132–3
  - immunosuppressive drugs 138

Cambridge University Press

978-1-904-75259-2 - Renal Disease in Pregnancy

Edited by John M Davison, Catherine Nelson-Piercy, Sean Kehoe and Philip Baker

Index

[More information](#)

## 266 | INDEX

- phosphate, total body, depletion, dialysis and 66
- phosphate binders 239
- phosphodiesterase 5 (PDE<sub>5</sub>) 10
- pituitary–gonadal axis, disturbances 168
- placenta
  - drug transfer across *see* transplacental drug passage
  - length, measurement 40
- placental abruption, chronic hypertension in CKD 153
- plasma exchange
  - HUS/TTP management 180, 181
  - lupus nephritis management 107
- plasma osmolality *see* osmolality (plasma/serum)
- plasma volume expansion
  - assessment 38
  - diuretics effect on 144, 160
  - mechanisms 8–10
    - renal sodium excretion signals 9–10, 32
    - volume perception in pregnancy 8–9
  - in normal pregnancy 3, 4, 5, 32, 141, 142
- podocytes
  - foot processes, in pre-eclampsia 190
  - VEGF secretion 11, 190
- podocyturia 190
- polyarteritis nodosa 98, 103, 104
- polycystic kidney disease, adult (APKD) 56
- polyhydramnios 63, 65
- postpartum care
  - consensus views 250–1
  - renal transplant recipients 84
- postpartum follow-up 53–7
  - by GPs 55
  - indications 54–6
  - by nephrologist 54–5
  - newly diagnosed renal disease 53, 54
    - with heritable component 56
  - plans 54
  - pre-existing renal disease 55–6
  - principles and rationale 53
- post-transplant erythrocytosis (PTE) 238–9
- post-transplant lymphoproliferative disorder (PTLD) 242
- pravastatin 239
- preconception care *see* pre-pregnancy care
- preconception counselling *see* pre-pregnancy counselling
- prednisolone 39, 134
  - lupus nephritis 105
  - metabolism 131
- pregnancy outcome and 134, 137
- pre-eclampsia 39–40
  - acute renal failure and 193
  - clinical presentation 189
  - in diabetic nephropathy 117
  - diagnostic difficulties 117, 192
  - differential diagnosis 192–3
    - active nephritis *vs* 97–8, 100
    - HUS/TTP *vs* 180, 193
  - renal biopsy not advised for 204
  - worsening renal disease *vs* 25
- hypocalciuria association 156
- increased protein excretion as marker 34, 40, 189–90
- indications for delivery 40
- in lupus nephritis 100, 103, 192
- management
  - antihypertensives 193–5
  - fluid balance 195–7
  - postnatal follow-up 197
  - see also* antihypertensive therapy; hypertension (maternal)
- maternal/fetal effects 40
- nephrotic syndrome due to 35, 190
- oedema 143
- overdiagnosis 192
- plasma uric acid as marker 37, 100
- preterm birth associated with dialysis and 63
- prevalence 151
- prevention, aspirin 25, 39, 233
- proteinuria levels 34, 40, 189–90, 204
  - persistence 54
- recurrence 197
- renal impairment in 189–99
  - differential diagnosis 192–3
  - management 193–7
  - postnatal follow-up 197
  - pre-existing renal disease *vs* 192
  - risk of 26
- renal pathophysiology 189–91
- renal transplant recipients 77, 229
- risk factors 39–40
- risk quantification in CKD 25
- severe
  - blood pressure control 195
  - fluid balance 195–7
- superimposed on CKD 39–40, 192
  - diagnostic features 40
  - monitoring, in hypertension 160
  - with pre-existing hypertension 151, 153, 155–6
  - prevention 155–6
  - recurrence 151
  - renal transplant recipients 77

- risk, percentages 153
  - time course 193
  - VEGF deficiency 13–14
  - without underlying CKD 35
- pregnancy
  - advice against 27, 123
  - incidence in diabetic nephropathy 112
  - incidence in dialysis patients 61–2
  - incidence in renal transplant recipients 62, 69, 170, 223
  - rates in lupus/vasculitic nephritis 96
- pregnancy-associated plasma protein A (PAPP-A) 40–1
- pregnancy outcome
  - in chronic hypertension in CKD 153–4
  - in CKD 31
  - in diabetic nephropathy *see* diabetic nephropathy
  - dialysis and *see* dialysis
  - in hepatitis C-positive patients 236
  - in hypertension 31, 32, 90, 105, 153–4
  - in lupus nephritis *see* lupus nephritis
  - reflux nephropathy effect 90–2
  - in renal/pancreas transplantation 226–7
  - in renal transplant recipients *see* renal transplant recipients
  - in uncontrolled hypertension 27
  - after urinary tract reconstruction 219
  - in vasculitic nephritis 103–4
  - in vesicoureteric reflux 91
- pregnancy tests, false positive 218
- premature birth *see* preterm birth
- prepregnancy care
  - consensus views 249
  - lupus nephritis 104, 107
  - renal transplant recipients 84
  - vasculitic nephritis 104, 107
- prepregnancy counselling 21–9, 28, 167
  - consensus views 249
  - drug use in pregnancy 22–3, 24–5, 129, 132, 140
  - indications 21–3
  - medication review 24–5
  - minimal data set requirement 23–4
  - role, risk awareness 21
  - timing of pregnancy 21, 24
- prepregnancy evaluation 23–5
- pressure natriuresis 9
- preterm birth 26
  - azathioprine association 135
  - chronic hypertension in CKD 153, 154
  - ciclosporin association 137, 139
  - diabetic nephropathy and 116, 117, 118–19
  - dialysis association 63, 67
  - elective delivery, diabetic nephropathy 118–19
  - lupus nephritis and 102, 241
  - renal transplant recipients 79, 171
  - risk of and risks associated 27
  - urinary tract infections associated 234
- preterm rupture of membranes, glucocorticosteroid use 134
- professional autonomy, midwife 47–8
- progesterone, serum, dialysis-induced reduction 64
- progestogen-only contraception 82
- prolactin, elevated 168, 170
- propranolol, adverse effects 158–9
- prostacyclin 156
- prostaglandins, ANCA-positive vasculitis 50
- protein/creatinine ratio (PCR)
  - measurement 34
  - in nephrotic syndrome 35
  - proteinuria definition 189
  - schedule of testing 41
- protein excretion
  - 24 hour, measurement 34
  - in CKD 33–6
    - disease progression risk 152
    - superimposed pre-eclampsia 40
  - in diabetic nephropathy 118
  - increase, as pre-eclampsia marker 34, 40
  - measurement 34
  - in nonpregnant woman 33
  - in normal pregnancy 33, 189
  - see also* proteinuria
- proteinuria 33–6
  - antenatal care 33–6
  - benign 34–5
  - causes 118
  - in CKD 133, 152
  - definition 96, 189
  - in diabetic nephropathy 114, 118, 121
  - in gestational hypertension 189
  - in hypertension with CKD, blood pressure target 152
  - low VEGF expression associated 13, 33–4
  - in lupus nephritis 96, 97, 101
  - measurement 34
  - orthostatic 35
  - postpartum follow-up 35–6, 54, 55
  - in pre-eclampsia 34, 40, 54, 189–90, 204
  - pregnancy outcome 90
  - prepregnancy counselling advice 24

Cambridge University Press

978-1-904-75259-2 - Renal Disease in Pregnancy

Edited by John M Davison, Catherine Nelson-Piercy, Sean Kehoe and Philip Baker

Index

[More information](#)

## 268 | INDEX

- renal transplant recipients 77, 231
- risk quantification in CKD by 25
- thromboembolic risk with 77
- see also* protein excretion
- proteinuric flares 98
- psychiatric morbidity 169
- psychomotor impairment 122
- psychosocial issues, in renal disease 169–70
- pulmonary oedema
  - in acute pyelonephritis 184
  - in diabetic nephropathy 118
- pyelonephritis, acute 91, 183–5
  - fetal risks 184
  - incidence in normal pregnancy 210, 234
  - management 184–5, 211, 234
  - maternal signs/symptoms 183–4
  - recurrent 185
  - in renal transplant recipients 234
- quinolones, avoidance 39
- radiation, fetal exposures, urinary tract imaging 212
- radionucleotide renography 213
- rapamycin *see* sirolimus
- red blood cell volume/mass, normal pregnancy 141, 142, 237
- reflux nephropathy 90–2
  - asymptomatic 90
  - epidemiology and clinical features 89–90
  - obstetric/maternal outcomes 90–2
  - postpartum follow-up 55, 56
  - renal scarring 89
  - urinary tract infections 90, 91
- rejection, acute, of renal graft 76, 140
- relaxin 7
  - acute administration 8
- renal amyloidosis 202
- renal angiomyolipoma (AML) 212, 217
- renal–antenatal clinic 28
- renal arteries, in renal transplantation 223
- renal biopsy 53, 201–6
  - in general nephrological practice 201–2
  - complications 201–2
  - contraindications 201
  - in pre-eclampsia 190
  - in pregnancy 202–4
    - complication rate 202, 203, 204
    - complications 202
    - contraindications 203, 204
    - ethics 203–4
    - in hypertension 203
    - indications 202–3, 204–5
    - safety 202, 203
    - technique 201
- renal calculi *see* renal stones
- renal cell carcinoma 217
- renal colic 224
- renal cortical necrosis *see* acute renal cortical necrosis (ARCN)
- renal disorders
  - chronic *see* chronic kidney disease
  - de novo*, postpartum follow-up 53, 54, 56
  - inherited 36
- renal dysfunction, definition 96
- renal dysplasia 89
- renal failure
  - acute *see* acute renal failure
  - in diabetes mellitus 111
  - in ovarian hyperstimulation syndrome 174
  - see also* renal impairment
- renal flares
  - definitions 98
  - in lupus nephritis *see* lupus nephritis
  - in vasculitic nephritis 98
- renal function
  - decline, in diabetic nephropathy 119–22
  - impairment in pre-eclampsia 189
  - loss, reflux nephropathy in pregnancy 91
  - normal adaptations in pregnancy 4
  - postpartum loss 54
  - in renal transplant recipients 71–4
    - differential diagnosis 75–6
    - hypertension effect 232
  - tests in CKD 41
- renal haemodynamics 5
- renal impairment
  - causes 192
  - definition 96
  - levels, risks associated 25–6
  - mild
    - risk quantification 25
    - risks in pregnancy associated 21, 22
  - moderate, risk quantification 26
  - pre-eclampsia-related renal impairment *vs* 192
  - risk quantification in CKD 25–7
  - serious, risk assessment 27
  - see also* renal failure
- renal obstruction, acute 182–3
- renal/pancreas transplantation 224–7
  - diet after 225
  - fertility and pregnancy after 226–7

Cambridge University Press

978-1-904-75259-2 - Renal Disease in Pregnancy

Edited by John M Davison, Catherine Nelson-Piercy, Sean Kehoe and Philip Baker

Index

[More information](#)

INDEX | 269

- in lupus 106
  - pregnancy outcomes 226–7
  - prognosis and benefits 226
- renal parenchymal disease, renal biopsy 205
- renal pelvis dilation 212
  - see also* hydronephrosis
- renal physiology 3–18
- renal plasma flow (RPF)
  - increased, in pregnancy 5, 8
  - in pre-eclampsia 189
- renal replacement therapy
  - in acute renal cortical necrosis 181
  - see also* dialysis; renal transplantation
- renal scarring 56, 89
- renal stones 185
  - detection 213, 214
  - dissolution 215
  - see also* urolithiasis
- renal tract
  - over-distended 183
  - rupture 183
- renal transplantation
  - pre-emptive, to reduce risk in
    - pregnancy 25–6
  - pregnancy outcome, *vs* renal/pancreas transplantation 226
  - principles and technique 223
  - ureteric obstruction 223–4
- renal transplant recipients 69–87
  - acute rejection risk 76
  - anaemia 143, 231, 237–8
  - assisted reproduction and 82–3, 175
  - bone/skeletal disorders 239–40
  - cardiovascular disease risk 232
  - comorbid conditions 229–45
    - management 230–1
  - contraception methods 82
  - criteria for pregnancy consideration 70
  - delivery mode/timing 79, 80, 224
  - diabetes with 231, 240–1
  - diabetic nephropathy 241
  - drug therapy 129–47
  - fertility issues 82–3
  - graft biopsy 76
  - graft survival 83
    - decline after pregnancy 74
  - haematological abnormalities 237–9
  - hyperlipidaemia 239
  - hypertension 76–7, 229, 232–3
  - infections 233–7
  - infertility rates 82
  - lupus nephritis in 231, 241
  - management plan in pregnancy 230
  - maternal life expectancy after
    - pregnancy 83
  - multiparity and multiple pregnancies 74–5
  - obstetric outcomes 77–80, 138
    - fetal growth 79
    - hypertension determining 77
    - perinatal mortality 78
    - preterm birth 79, 137, 139
  - osteoporosis 239
  - outcomes in children of 80, 81, 138
  - post-transplant erythrocytosis 238–9
  - pre-eclampsia 77, 229
    - risk reduction 233
  - pregnancy effect on 71
  - pregnancy incidence/numbers 62, 69, 170, 223
  - preparation for pregnancy 83, 84
  - proteinuria 77, 231
  - renal function during/after 71–4
    - differential diagnosis 75–6
  - second transplants, and pregnancy 171
  - SLE 241
  - thromboembolism risk 77, 240
  - timing of pregnancy 64, 70, 223
  - tumours 241–2
  - unplanned pregnancy 70, 82, 170
  - urate excretion 37, 75
  - ureteric obstruction 223–4
  - urinary tract infections 233–4
    - management plan 230
  - viral infections 235–7
- renal trauma 217
  - acute, renal biopsy 205
- renal tubular acidosis, type I 37
- renal tubular function, assessment 36–7
- renal tumours 217
- renal ultrasound
  - postpartum follow-up and 53, 55
  - in urinary tract infections 38
- renal vasodilation 4–5
  - in early normal pregnancy 5
  - nitric oxide-dependent 5–6
    - signalling events leading to 6–8
  - prevention, relaxin removal 7
  - relaxin mediating 7–8
  - systemic vasodilation relationship 4–5
- renal vein compression 217
- renin-angiotensin-aldosterone (RAAS) system 5, 8
  - inhibitor in CKD (nonpregnant women) 152
- renography, radionuclide 213
- research, consensus views 251
- respiratory alkalosis 66, 215
- respiratory distress syndrome 229

## 270 | INDEX

- retinopathy, diabetic 113, 122
- ribavirin, contraindication 236
- risk awareness 21
- risk–benefit analysis, of pregnancy 27
- risk quantification, in CKD 25–7
- risks of pregnancy
  - education of physicians on 28
  - in mild renal impairment 21, 22, 25
  - in moderate renal impairment 26
  - older women with CKD 27
  - in renal transplant recipients 25–6
  - in serious renal impairment 27
  - see also individual conditions*
- rituximab 76, 106
- rubella 235
- saline, intravenous 38
- screening
  - bacteriuria 90, 183, 211, 234
  - diabetic nephropathy comorbidity 115
  - vesicoureteric reflux 90, 92
- seizures, prophylaxis in pre-eclampsia 197
- sepsis
  - maternal death in lupus nephritis 102, 105, 107
  - urinary *see* urinary tract infections
- septic shock 184
- sevelamer, avoidance 239
- sexual dysfunction, in CKD 62, 167–70
  - hormonal disturbances 168
  - in men 169–70
  - prevalence 167–8
  - psychosocial issues 169–70
- sFlt<sub>1</sub> 13, 14
  - increase in pre-eclampsia 13, 14, 33–4, 151
  - VEGF deficiency associated 13, 14, 33–4
- shared responsibility 47
- shoulder dystocia 122
- signalling
  - NO-dependent renal vasodilation 6–8
  - renal sodium excretion 9–10
  - VEGF 190
- simvastatin 239
- sirolimus 141
  - avoidance in pregnancy 24
  - breastfeeding and 141
  - pregnancy outcome 141
- skin disease/features
  - Henoch-Schönlein purpura 99
  - lupus 98
- SLE *see* systemic lupus erythematosus (SLE)
- small-for-gestational-age infants
  - beta-adrenergic blockers associated 160
  - in chronic hypertension in CKD 153, 154, 162
  - ciclosporin association 137, 139
  - in lupus nephritis 106
- smoking cessation 55
- social needs of women, midwife's role in recognising 49
- sodium
  - renal excretion 9–10, 215
  - renal retention 8, 9
- soluble fms-like tyrosine kinase I (sFlt<sub>1</sub>) *see* sFlt<sub>1</sub>
- sphygmomanometry, mercury 32
- spironolactone 144
- statins, teratogenicity 24, 239
- sterilisation, renal transplant recipients 82
- stillbirths, in diabetic nephropathy 119
- stress, after renal/pancreas transplantation 226
- stress urinary incontinence 210
- Study in Transplantation Empowering Patients and Practitioners (STEPP) 83
- subfertility
  - management 167
  - renal transplant recipients 170
  - see also* infertility
- surgery
  - renal/pancreas transplantation 224–7
  - renal transplantation 223–4
- sympathetic nervous system, normal pregnancy 9
- systemic lupus erythematosus (SLE)
  - autoantibodies 75
  - extrarenal disease 98
  - renal disease *see* lupus nephritis
  - in renal transplant recipients 231, 241
- Systemic Lupus Erythematosus Disease Activity Index (SLEDAI-2K) 98
- systolic blood pressure
  - kidney disease progression risk 152
  - target, in hypertension 160, 194
- systolic hypertension 149
- tacrolimus 39, 136–9
  - breastfeeding and 139
  - diabetes risk 240–1
  - glucose intolerance risk 240–1
  - in lupus nephritis 106
  - pharmacokinetics 138
  - renal transplant recipients 78, 136–9
- Takayasu's arteritis 98, 104
- teratogenicity 24, 25, 129–30
  - detection 130
  - dose–response relationship 131

Cambridge University Press

978-1-904-75259-2 - Renal Disease in Pregnancy

Edited by John M Davison, Catherine Nelson-Piercy, Sean Kehoe and Philip Baker

Index

[More information](#)

INDEX | 271

- latent period 130
- preclinical/animal studies 130
- susceptibility 131
  - see also* congenital abnormalities; individual drugs
- teratogens 129
- termination of pregnancy, therapeutic
  - lupus nephritis 106
  - renal transplant recipients 78, 82
- thrombocytopenia 40
  - in HUS/TTP 180
  - in lupus 98
- thromboembolism
  - in diabetic nephropathy 115, 117
  - risk in renal transplant recipients 77, 240
- thrombotic microangiopathies, differential diagnosis 193
- thrombotic thrombocytopenic purpura (TTP) 179
  - see also* haemolytic uraemic syndrome/ thrombotic thrombocytopenic purpura (HUS/TTP)
- thromboxane A<sub>2</sub> 156
- timing of pregnancy
  - prepregnancy counselling 21, 24
  - renal transplant recipients 64, 70, 223
- T lymphocytes 80
- toxoplasmosis 237
- transforming growth factor  $\beta$  (TGF $\beta$ ) co-receptor 13
- transitional cell carcinoma 217, 218
- transplacental drug passage
  - antihypertensives 158
  - azathioprine 135
  - ciclosporin 136
  - diuretics 144
  - factors affecting 131
  - glucocorticosteroids 134
  - mycophenolic acid, enteric-coated (MPA) 139
- transurethral resection of bladder tumour (TURBT) 217–18
- trimethoprim 39, 234
- tubulo-interstitial disorders 37
- tumours
  - lower urinary tract 217–18
  - post-renal transplant 241–2
  - upper renal tract 217
- UK National Teratology Information Service 132
- UK Transplant Pregnancy Registry (UKTPR) 71, 72–3, 227
- ultrasound
  - acute pyelonephritis management 185, 211
  - fetal, maternal dialysis and 66
  - fetal wellbeing assessment 40, 160
  - renal function assessment in renal transplantation 76
  - renal pelvis dilation detection 212
  - transabdominal 212
  - transvaginal 213
  - ureteric dilation detection 212, 213
  - ureteric stone detection 213
    - see also* renal ultrasound
  - umbilical artery pulsatility index 64
  - ‘underfilled’ state/theory 8, 9
  - unplanned pregnancy, renal transplant recipients 70, 82, 170
  - uraemia, in acute renal cortical necrosis 181
  - ureteric colic, management 215
  - ureteric dilation 209
    - detection 212, 213
  - ureteric obstruction 209, 211–12
    - detection by imaging 213
    - management 224
    - partial 224
    - renal transplantation and 223–4
    - at site of ureteric re-implantation 218
    - transplant ureter 224
  - ureteric re-implantation 218
  - ureteric stent
    - double-J 214, 215
    - J-stent 224
  - ureteric stone, diagnosis 213, 214
  - ureteropyelography, retrograde 214
  - ureteroscopy 216
    - contraindications 216
  - urethra, congenital abnormalities 182
  - uric acid/urate
    - elevated, pre-eclampsia 100
    - excretion and reabsorption 37
    - excretion in renal transplant recipients 37, 75
    - plasma level as pre-eclampsia marker 37
  - urinalysis, protein excretion prediction 34
  - urinary casts 97
  - urinary catheterisation 210
  - urinary frequency 210, 217
  - urinary incontinence 210
  - urinary retention 210
  - urinary tract
    - bowel segment incorporation 218
    - diversion 218
    - imaging 212–14
      - fetal radiation exposure 212

Cambridge University Press

978-1-904-75259-2 - Renal Disease in Pregnancy

Edited by John M Davison, Catherine Nelson-Piercy, Sean Kehoe and Philip Baker

Index

[More information](#)

## 272 | INDEX

- lower tract
  - physiological changes 209–10
  - symptoms 210
  - tumours 217–18
- obstruction
  - acute renal 182–3
  - detection 185
  - see also* ureteric obstruction
- physiological changes in pregnancy 209–10
- reconstruction 218–19
- stones *see* urolithiasis
- tumours 216–18
- upper tract
  - pain and imaging 211–14
  - physiological changes 209
  - tumours 217
- urinary tract infections (UTIs) 37–8, 210–11
  - antenatal care 37–8
  - causative organisms 38, 211, 234
  - in CKD 36
  - diagnosis 37
  - management 38, 39
  - recurrent, pre-pregnancy counselling 23
  - in reflux nephropathy 90, 91
  - in renal transplant recipients 233–4
  - management plan 230
  - risk and risk factors 211, 233–4
  - vesicoureteric reflux and 90, 91
- urinary urgency 210, 217
- urine culture 37, 38, 41
  - midstream (MSU) 211
- urine output, in pre-eclampsia 196
- urinoma 183
- urolithiasis 185, 214–16
  - detection 213, 214
  - management 215–16
  - metabolic changes leading to 214–15
  - microscopic haematuria 217
- urological conditions in pregnancy 209–20
- uropathy, obstructive *see* obstructive uropathy; ureteric obstruction
- US National Kidney Foundation 133
- US NTPR *see* National Transplantation Pregnancy Register (NTPR)
- uterine artery pulsatility index 40
- uterine–umbilical artery blood flow, dialysis patients 66
- uteroplacental ischaemia, increased Flt<sub>1</sub> 13
- uteroplacental vasculopathy, surveillance 161
- uterus, retroversion 210
- vaccinations, childhood 80
- vaginal delivery
  - contraindications 218
  - renal transplant recipients 79
  - after urinary tract reconstruction 218
- vascular endothelial growth factor (VEGF) 3–4, 11–14
  - deficiency in pre-eclampsia 13–14
  - sFlt<sub>1</sub> role 13, 14, 33–4
  - depletion effects 11, 34
  - excess/overexpression 11, 13, 14
  - functions/role/actions 11, 12
  - injury exacerbated by 13
  - podocyte-derived 11, 190
  - receptors 11, 12
  - see also* Flt<sub>1</sub>
  - in renal disease 11, 13, 34
  - signalling 190
  - VEGF-A 11
- vascular smooth muscle (VSM), VEGF receptor expression 11
- vasculitic nephritis
  - burnt-out disease 97–8
  - diagnosis 97
  - disease activity 98
  - epidemiology 95–6
  - haematuria 96, 97
  - management 104–7
  - steroid dosage 105
  - summary/key factors 107
  - maternal death 104
  - pre-eclampsia *vs* 97–8
  - pregnancy and 103–4
  - pregnancy rates 96
  - pre-pregnancy counselling 23
  - renal flare 98
- vasculitis 95–109
  - definition 97
  - extrarenal disease 97–8, 99
  - medium–large vessel 95, 99
  - pregnancy outcomes 103–4
  - renal disease 97–8
  - small vessel 95
- vasoactive factors 5–6
- vasoconstriction
  - decrease in normal pregnancy 9
  - in diabetic nephropathy 117
  - in hypertension, management 151
- vasodilation
  - primary 3
  - renal *see* renal vasodilation
  - systemic, in early normal pregnancy 5, 150
- verapamil 160
- very low birthweight infants, renal

Cambridge University Press

978-1-904-75259-2 - Renal Disease in Pregnancy

Edited by John M Davison, Catherine Nelson-Piercy, Sean Kehoe and Philip Baker

Index

[More information](#)

INDEX | 273

- transplant recipients 79
- vesicoureteric reflux (VUR) 23, 89–90
  - familial 89
  - incidence 89
  - obstetric and maternal outcome 91
  - postpartum follow-up 56
  - screening 90, 92
  - urinary tract infection 90, 91
- viral infections, renal transplant recipients 235–7
- vitamin(s), water-soluble 66
- vitamin C 156, 233
- vitamin D, in nephrotic syndrome 35
- vitamin E 156, 233
- Vitamin in Pregnancy (VIP) trial 156
- volume expansion *see* plasma volume expansion
- volume homeostasis 38
- volume perception in pregnancy 8–9
- Wegener's granulomatosis 99, 104
- weight gain, dialysis patients 65
- women
  - autonomy, promotion by midwives 47, 48
  - experience of midwifery care 47–8
  - rights to be parent 171
- wound healing, impairment, sirolimus/everolimus causing 141